Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Blood biomarker may predict Parkinson’s disease progression

Key clinical point: Neurofilament light chain is the first blood biomarker for Parkinson’s disease progression.

Major finding: Neurofilament light chain in the cerebrospinal fluid can distinguish Parkinson’s disease from multiple system atrophy and progressive supranuclear palsy.

Study details: A retrospective analysis of 514 serum samples).

Disclosures: The study was funded by the Michael J. Fox Foundation for Parkinson’s Research. Dr. Vaou had no relevant financial disclosures.


Mollenhauer B et al. Mov Disord. 2020 Aug 15. doi: 10.1002/mds.28206.